Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, will participate in a panel discussion at Biotech Showcase 2016.
Moderated by Andrew Baum, global head of equity research at Citi, the panel, entitled, Investing in the Immuno-Oncology Revolution: Follow the T Cells, will occur on Wednesday, January 13, from 8:00 a.m. - 8:55 a.m. PST at the Parc-55 Hotel in San Francisco. In addition to Mr. Mansour, the workshop will feature additional leaders in the immuno-oncology space.
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during one of the industry's largest annual healthcare investor conferences. Now in its eighth year, it features more than 300 public and private corporate presentations and more than 2,300 attendees.
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
Connect at www.imvaccine.com
Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
For more information, contact:
Sam Brown Inc.
Halifax, Nova Scotia, January 7, 2016